Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
- PMID: 33438115
- DOI: 10.1007/s11864-020-00814-z
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
Abstract
The treatment for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years with a deeper understanding of the molecular make-up of the disease and the clinical development of therapies with novel mechanisms of action. While some patients with more indolent disease may benefit from local therapy such as metastasectomy or cytoreductive nephrectomy, others may safely embark on an active surveillance program or be offered targeted therapy. Yet, a combination regimen including an ICI is the most effective regimen and should be considered in most mRCC cases. Ongoing studies will help determine which factors can be further used to optimize treatment selection and personalize disease management.
Keywords: Immune checkpoint inhibitors; Kidney cancer; Renal cell carcinoma.
References
References and Recommended Reading
-
- Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215:2477–9. https://doi.org/10.1084/jem.20181617 . - DOI - PubMed - PMC
-
- Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67:507–24. https://doi.org/10.3322/caac.21411 . - DOI - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590 . - DOI
-
- American Cancer Society. Survival rates for kidney cancer. https://www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/... . Accessed 22 Apr 2020.
-
- National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html . Accessed 22 Apr 2020.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical